



Creating value in hospital
pharmaceuticals



Global power, local service



One of the world's leading generics companies, Actavis has built a powerful reputation for high quality pharmaceuticals, with a broad and growing portfolio of products manufactured in highly regulated countries.

Increasingly, Actavis is working with hospitals to deliver efficient and innovative solutions. At the heart of our approach is a genuine understanding of local needs, combined with the obvious advantages of an established global operation.

From flexibility and differentiation in terms of its products and presentations, for example gemcitabine solution and docetaxel, to the value and service it provides, Actavis offers hospitals a relationship that is as refreshing as it is reliable.

Providing a global service, tailored to local needs

Safe, reliable products

Actavis offers fast access to a wide choice of pharmaceuticals. We operate contemporary GMP-approved* manufacturing facilities in Europe, with meticulous in-house quality standards and rigorous regulatory environments ensuring the highest quality at all times. This quality is reflected in our commercial customer base, which includes a number of leading businesses, for example Pfizer.

Actavis produces in excess of eight million vials for oncology treatments each year, providing freeze-dried and solution products, as well as high volumes of cytotoxic and non-cytotoxic injectables, for sale primarily across Europe, the US and Japan.

**Good Manufacturing Practice (GMP): European Medicines Agency (EMA), USA Food and Drug Administration (FDA)*

*Offering high-quality pharmaceuticals
to an extensive customer base*



Supply on demand

Actavis has a robust supply chain that is more flexible than many of our competitors'. We hold bulk supplies of undifferentiated, near-finished goods which can then be finalised quickly and efficiently for different markets – especially reassuring for anyone who has experienced stock-out situations.

As a relative newcomer to the field of hospital medicines, we have had the advantage of being able to design an appropriate supply chain from scratch, unlike more mature incumbents. Reduced lead times, enhanced flexibility and improved customer service are among the factors contributing to the growth of Actavis in the hospital sector.

Helping to maintain continuity in patient care





A growing portfolio

Actavis now markets over 200 hospital products, a number that is rising rapidly, with around 650 applications pending worldwide for injectable medicines. In addition is an ambitious development pipeline with around 47 further new hospitals applications expected to be submitted during 2011/12.

Actavis has always been determined to create value at every level of its business, a commitment evident in our portfolio of affordable, reliable products. By bringing to market a comprehensive range of high quality medicines, Actavis spurs greater competition in the sector, ultimately freeing up funds for hospitals.

In addition to oncology medicines, Actavis also markets a growing range of anti-infectives, local anaesthetics and analgesics.

Delivering fast, easy access to a wide range of products

Active protection

Actavis is targeting the safety of clinicians and patients in a variety of ways, all of which play important roles in reducing error and wastage, whilst increasing efficiency.

- **New presentations** – building on detailed consultation in over 40 markets, Actavis continues to develop new and often unique presentations in more appropriate doses (which need less manipulation) and formulations that are quicker to reconstitute as necessary. Recent developments include ready to use mini-bags and reformulations of old powder-form cytotoxic pharmaceuticals.
- **Protective technologies** – most markets can now order oncology products with either PVC-free Onco-Guard® or PVC-free VialShield™ technologies, specially designed to minimise breakage and occupational exposure to highly toxic agents. Upgraded packaging also makes it clearer exactly what each pack contains and how it should be used.
- **Supportive documentation** – Actavis offers extended physico-chemical stability data for major cytotoxics and additionally can make available comprehensive detail on its first class vial washing protocols

Together these improvements help protect clinicians, patients and hospital reputations by reducing handling errors and illness related to cytotoxic exposure.

Enhancing safety and efficiency within hospitals



Caring for the environment

Actavis is committed to protecting the environment and this is demonstrated by tangible actions not just words:

- Environmental Management Systems at our all of our hospital product manufacturing sites have achieved **ISO 14001** certification, providing independent reassurance that our systems meet internationally recognised standards.
- **Actavis' Energy Management Programme** has been set up to improve energy efficiency and source renewable options where possible. Our Icelandic site runs on sustainable energy, using geothermal power for heating & electricity.
- In 2009, Actavis scientists **reduced the freeze drying cycle time** for Gemcitabine at its Italian facility by over 40%. Freeze drying is one of the most energy-intensive production processes so this dramatically reduces the environmental impact of the product.
- Our injectable have also upgraded its Vial-Shield™ protective technology **PVC free**.
- Our injectable product manufacturing facilities are located close to our main European customer base, reducing transportation and **minimising our carbon footprint**.





www.actavis.com

 **actavis**